Interestingly, belimumab is a monoclonal antibody targeting human BAFF and was the first targeted therapy approved for SLE [72,73,74], highlighting the potential for drug repurposing for genetically related conditions. Here, TNFSF13B is linked to systemic lupus erythematosus.